Abstract. Low density lipoprotein receptor-related protein (LRP) is a multifunctional cell surface receptor binding many different ligands including proteinases and their inhibitors, some of which are known to be involved in tumor biology. We studied the expression of LRP and its putative role in colorectal carcinoma. Tissue samples were obtained from 50 patients with colorectal carcinoma and fixed in formalin and embedded in paraffin. Immunohistochemical staining was performed using antibodies directed against LRP, cathepsin B and urokinase-type plasminogen activator (u-PA). The expression of LRP was further studied by polymerase chain reaction. UICC (p=0.038 and 0.018, respectively). We provide evidence that LRP is expressed in colorectal cancer. As LRP forms complexes with u-PA and its inhibitor, we suspect that LRP can influence the known effects of u-PA on tumor biology.
Introduction
Colorectal cancer is the most common malignant tumor of the gastrointestinal tract (1) . Its prognosis depends on many different factors, including local tumor growth, vascular invasion, reactive changes in regional lymph nodes, local signs of inflammation, completeness of tumor resection and distance of the tumor to the resection margins. The prognosis also depends on the histological grade of tumor differentiation, certain genetic markers and the expression of proteolytic enzymes (1) .
There is abundant evidence that proteinases are involved in the tumor biology of colorectal cancer. Their ability to degrade components of the extracellular matrix (ECM) contributes to tumor cell invasion and metastasis (2) . Former studies have shown that cathepsin B and u-PA are among the proteinases expressed in colorectal cancer (3, 4) .
Cathepsin B is a lysosomal cystein proteinase (5) that contributes directly to invasive growth and metastatic potential of malignant tumors by degrading ECM proteins (2, 6, 7) . Furthermore, cathepsin B can activate pro-u-PA, prorenin and procollagenase (8) (9) (10) . In malignant cells cathepsin B could not only be found in lysosomes but also along the cell surface where its presence increases with the metastatic potential of the tumor cell (11, 12) . Along the cellular membrane cathepsin B seems to be bound to · 2 -macroglobulin, which is in contact with the membrane via the low density lipoprotein receptor-related protein (LRP) (13) .
The plasminogen activators u-PA and t-PA are serine proteases. They convert plasminogen into active plasmin, which does not only act in thrombolysis but can also degrade components of the ECM (2, 14) . Plasmin activates several prometalloproteinases that are also involved in the degradation of the ECM (2, 15, 16) . Even though those two plasminogen activators resemble each other in their structure and function, there are few differences. t-PA mainly seems to produce the active form of plasmin for thrombolysis whereas u-PA seems to be involved in processes of tissue rearrangement (2, 16, 17) . Pro-u-PA, the inactive single-chain form, is produced by many different malignant and non-neoplastic cells, including colorectal cancer (18, 19) . Plasmin and cathepsin B can serve as activators of pro-u-PA (9, 16, (19) (20) (21) . On the cell surface pro-u-PA binds u-PAR and is then activated without losing its affinity to u-PAR. By binding to u-PAR proteolytic activity is concentrated on the cell surface and plasminogen activation increases by ~16-fold (2, 22, 23) . When u-PA is bound to u-PAR and reacts with its specific inhibitor PAI-1, the whole complex is endocytosed by an LRP-depending mechanism. LRP is ONCOLOGY REPORTS 17: 361-367, 2007 
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The expression of low density lipoprotein receptor-related protein in colorectal carcinoma binding u-PAR as well as the complex of u-PA:PAI-1 (24) (25) (26) . This association of LRP and u-PAR is persistent in the early endosomes after internalisation of this whole complex. Then u-PA:PAI-1 separates from the receptor complex for degradation in lysosomes (24, 25) . Vacant u-PAR and LRP now dissociate from each other and return to the cell surface via recycling vesicles, where they are available for new ligandbinding again (24, 25, 27) . This process is regulated by PAI on the one hand because it hinders u-PA from activating plasminogen and leads to the internalisation and degradation of u-PA. On the other hand it is regulated by LRP which is essential for this cellular uptake and the recycling of vacant receptors to the cell surface (24) . In human trophoblast cells, blocking LRP by specific antibodies or by RAP leads to a 50% reduction of cell surface PA-activity and to a delayed regeneration of free u-PAR because, without LRP, inactivated complexes of u-PA:PAI-1 cannot be removed from the cell surface and vacant receptors cannot be recycled (28) . Apart from its activation of plasminogen, u-PA is also involved in processes of cellular migration, adhesion, and differentiation via its link to PAI-1 and to u-PAR. PAI-1 has a high-grade affinity to vitronectin that can accelerate migration of smooth muscle cells significantly and to its receptor, vitronectin receptor integrin · v ß 3 , that is needed for cell motility. By binding to u-PA PAI-1 loses its affinity to vitronectin (29) . u-PAR is associated with several cell surface integrins that are involved in cell-cell interactions, migration and adhesion (30, 31) . Furthermore, some signal pathways are initialized by binding u-PA to u-PAR that are again linked to cell migration and invasion (32) (33) (34) .
Thus, while cathepsin B and u-PA have been found in colorectal cancer, and cellular metabolism of cathepsin B and u-PA are regulated by LRP, to the best of our knowledge, until now the expression of LRP in colorectal cancer has not Table I . Patient characteristics. 
been studied. Here we investigated the expression of LRP in colorectal cancer, its spatial relation to cathepsin B and u-PA and whether it bears the potential of influencing colorectal cancer biology.
Materials and methods

Materials.
Tissue samples from 50 patients (31 men, 19 women; mean age, 63.3±13.4 years; range, 35-91 years) suffering from cancer of the rectum or sigma were retrieved from the archive of the Department of Pathology of the Ottovon-Guericke-University, Magdeburg, Germany. All patients had undergone recto-sigmoidectomy between 1996 and 1998. Twenty-two of them were suffering from rectal cancer, 20 from sigmoidal cancer and 8 from cancer involving both, the sigma and rectum (Table I) .
Tissue samples were collected directly after tumor resection and either snap-frozen in liquid nitrogen and stored at -80˚C, or fixed in 4% buffered formalin and embedded in paraffin. For immunohistochemical staining tissue samples were chosen that enclosed tumor and non-neoplastic mucosa.
Histology. All resection specimens underwent routine surgical pathological examination, which included histological investigation of the tumor and non-neoplastic mucosa, the surgical margins and all lymph nodes present in the resection specimen. Deparaffinized sections were stained with hematoxylin and eosin. The TNM staging was determined according to the UICC guidelines (35) .
Immunohistochemistry. For immunohistochemistry, 3-to 5-μm thick paraffin sections were placed onto SuperFrost 2+ glass slides, deparaffinized in xylol (3x5 min) and rehydrated in a graded alcohol series (100, 100, 96 and 75%). Immunostaining was performed with murine monoclonal antibodies directed against LRP ·-chain (dilution 1:10), LRP ß-chain (1:10; both American Diagnostica Inc., Greenwich, USA), u-PA (1:20; Technoclone, Vienna, Austria) and a sheep monoclonal antibody directed against cathepsin B (1:60; BioGenex Laboratories, San Ramon, USA). Incubation with the primary antibodies was carried out in a moist chamber at 37˚C for 30 min (u-PA; cathepsin B) or 1 h (LRP). Biotinylated polyvalent anti-rabbit IgG (30 min, room temperature; Immunotech, Marseilles, France) or biotinylated mouse-anti-sheep antibodies (Dako, Hamburg, Germany) served as secondary antibodies. Slides were washed between steps with Tris-buffered saline (TBS). Immunoreactions were visualized via an avidinbiotin complex, using the Vectastain ABC alkaline phosphatase kit (Vector Laboratories Inc., Burlingame, USA) or the Ventana Nexes immunostainer and the Ventana Basic DAB detection kit (Ventana Medical Systems, Starsbourg, France). Fast red/ Naphthol Mx (Immunotech) or 3'3 diaminobenzidine served as chromogens. Immunostaining of LRP necessitated antigen retrieval with Proteinase K at 37˚C for 30 min. The specimens were counterstained with hematoxylin. Breast cancer tissue served as positive control. Omission of primary antibodies served as a negative control.
Polymerase chain reaction. LRP-mRNA was searched in unfixed tissue samples obtained from 12 of the patients also studied by immunohistochemistry. Using TRIzol reagent (Invitrogen), we extracted total cellular RNA according to the manufacturer's instructions. RNA was reverse-transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers by Omniscript™-reverse transcriptase (Qiagen GmbH). Amplification of LRP cDNA was performed with the primers: LRP-1 3':5'-CTACTGGCTC GTTCTTGGCC-3' and 3v LRP-1 5':5'-CCTCATCTGAGC CGTCCATG-3'. The integrity of RNA and adequate cDNA synthesis was confirmed by using ß-actin specific primers. Complete PCRs were initially heated to 94˚C for 5 min for denaturation, and specific fragments were amplified in 30 cycles (0.5 min at 94˚C, 1 min at 58 or 64˚C and 1.5 min at 72˚C). The PCR products were analyzed on a 0.8% agarose gel stained with ethidium bromide. The oligonucleotide primers were custom synthesized by Invitek (Berlin, Germany).
Statistics. The correlation coefficient after Pearson and thē
2 -test were used. A p-value of <0.05 was considered significant.
Results
LRP.
Using a monoclonal antibody directed against the ·-chain of LRP we found LRP in the colorectal cancers of 47 (94%) patients (Fig. 1) . Immunostaining was usually faint and present in the non-neoplastic stroma cells Interestingly, LRP-expression was inhomogenous, i.e., in 11 (22%) patients immunostaining was more prominent at the invasion front and weaker or absent in the tumor centre. A similar expression pattern was found with an anti-LRP antibody directed against the ß-chain. No immunostaining was observed after the omission of the primary antibody. Using PCR, we found LRP-mRNA in the tumor samples of 2 patients. In 10 patients LRP-mRNA was below detection level. In contrast, ß-actin-mRNA was found in every case (Fig. 2) . Statistics. Statistical analyses showed a significant correlation between the prevalence of LRP-and u-PA-expression for smooth muscle cells (p=0.027) and cells of the tumor stroma (p=0.043). Furthermore, all samples were staged according to UICC classification. Concerning LRP, a significant correlation was found between the LRP-expression of tumor cells and tumor stage (p=0.038). u-PA showed a significant correlation between the cells of non-neoplastic stroma (p=0.007) and tumor cells (p=0.018). The prevalence and spatial distribution of cathepsin B did not show any correlation with the expression of LRP, u-PA or any TNM-category. 
Discussion
LRP is a member of the low density lipoprotein receptor family (LDLR family). This family comprises LRP, low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor 2 (ApoER2), multiple epidermal growth factor-containing protein 7, megalin/glycoprotein-330 (gp-330), MEGF7, LRP-1B, LRP-5 and LRP-6 (27, (36) (37) (38) . All of these proteins have some homologue domains in common but differ in their molecular masses and ligands (36) . LRP consists of five domains: the ligand-binding cystein-rich repeats, the epidermal growth factor (EGF) receptor-like cystein-rich repeats, the YWTD domains, a membrane-spanning segment, and a cytoplasmatic tail that includes two NPxY motifs (2) .
LRP is a cell surface receptor that can frequently be found in the liver, placenta and brain. It is also expressed by epithelial cells of the digestive system, smooth muscle cells, macrophages and fibroblasts (39, 40) . It is characterized by its enormous number of different ligands and its wide spectrum of biological functions. The extracellular region with its four ligand-binding clusters recognizes at least 30 different ligands among which lipoproteins, proteinases and their inhibitors, proteins of the extracellular matrix (ECM), infectious agents such as bacterial toxins and viruses, and many other proteins can be found (41) . At first, LRP was thought to primarily serve as a lipoprotein receptor due to its resemblance to LDLR (42) (43) (44) (45) . Later, LRP was found to bind the proteinase inhibitor · 2 -macroglobulin and it was discovered that it is identical to the · 2 -macroglobulin receptor (42, 46, 47) . The far biggest group of ligands however, seems to be formed by proteinases and their inhibitors among which the plasminogen activators t-PA and u-PA play a special role. LRP binds these proteinases as a complex with their inhibitors, such as PAI-1, to mediate their cellular uptake and lysosomal degradation (25, 26) . Furthermore, LRP also binds to the special u-PA receptor (u-PAR) which is needed for the cellular uptake of u-PA:PAI-1 complexes (24) .
We believe that we are the first to demonstrate the expression of LRP in colorectal cancer tissue. Despite using a relatively high concentration of the primary antibodies, we believe that immunostaining was specific for LRP for the following reasons: i) the negative controls never showed any immunoreaction excluding false positive staining related to the detection system or the secondary antibodies; ii) a second primary antibody directed against the ß-chain of LRP showed a similar staining pattern to the antibody directed against the ·-chain; iii) the expression pattern of LRP observed in our series largely corresponds to observations made by others. LRP is supposed to be found mostly in cells of the stroma such as fibroblasts (39, 48, 49) . Moreover, cells of the central nervous system, hepatocytes, placental cells, adipocytes, monocytes, macrophages and smooth muscle cells express LRP (38) (39) (40) . Here we found LRP in stromal cells, smooth muscle cells, in the tumor-accompanying desmoplastic stroma, and even in fat cells. These observations are in accordance with those described in the literature (38, 39, 48, 49) . iv) Finally, LRP-mRNA was found by PCR in at least a few patients studied immunohistochemically. However, in the majority of our patients LRP-mRNA content was below the detection limit and might contribute to a low expression level.
In this study we found a decreasing expression of LRP in tumor cells with increasing tumor stages. Several other authors also showed decreasing LRP depending on the tumor stage (24) . 1, active u-PA is bound to u-PAR and catalyses production of plasmin, by binding PAI-1 u-PA is inactivated; 2, the complex of u-PA and PAI-1 binds to LRP and mediates the interaction of LRP and u-PAR; 3, this complex of 4 components is being internalised; 4, u-PA:PAI dissociates from the receptors and is degraded; 5, LRP and u-PAR dissociate from each other; and 6, return to the cell surface in recycling vesicles. migration on vitronectin-covered surfaces and their invasion in matrigel was accelerated (14, 52) . As accelerated invasion and migration are advantageous for malignant tumors, according to these observations rather low levels of LRP in malignant tumors would be suspected.
Other authors showed an increased expression of LRP in malignant tumors (53) . This contradiction might be explained by the many different metabolic processes LRP takes place in. Increased availability of LRP on the cell surface can lead to an increased regeneration of free u-PAR that in turn binds u-PA to the cell surface and, thus, increases the local proteolytic activity. Inactive pro-u-PA binds to u-PAR and is converted into its active form u-PA that is proteolytically active and takes part in tumor biology (22, 23) . If then PAI-1 binds to u-PA and inhibits its activity, the whole complex of those three proteins is taken up into the cell via LRP. u-PA and its inhibitor are degraded in lysosomes while LRP and u-PAR dissociate from each other and return to the cell surface in order to receive new ligands. Fig. 3 illustrates the biological mechanism of LRP-mediated u-PAR recycling. As LRP is responsible for the uptake of this complex it might be assumed that an increased production of LRP could lead to an increase in proteolytic activity because it clears the cell surface from these inactive complexes and regenerates free u-PAR (24, 26) . Yamamoto et al showed a correlation of increased expression of LRP, expression of u-PA, and malignancy of astrocytomas (53) . Furthermore, Zhang et al demonstrated a decline in the activity of u-PA and reduction in the regeneration of free u-PAR when LRP was inhibited by RAP or antibodies (28) . Cellular uptake and degradation of proteinases is not the only way in which LRP can influence tumor growth and metastasis. LRP is also responsible for the uptake of apo-E-enriched lipoproteins. Fabrizi et al showed reduced expression of LRP in differentiated cells of neuroblastoma and explained it with the lower demand for cholesterol and lipids of differentiated cells due to their lower mitotic index compared to dedifferentiated cells (54) . It could be assumed that cells with high mitotic indices express more LRP because they need more cholesterol and lipids for membrane production. Maybe these circumstances lead to the higher expression of LRP in the invasion zone described in 22% of our samples.
In addition to LRP we also studied the expression of u-PA and cathepsin B in colorectal carcinoma. We found cathepsin B in tumor and accompanying tissue of each sample. For colorectal cancer the expression of cathepsin B has been described to correlate with the grade of differentiation and the tumor stage (3) and was not confirmed in our series. However, the number of cases was probably too small and we were mainly interested to show that LRP-expressing colorectal cancers also express cathepsin B. Similarly, we were able to show that LRP-expressing colorectal cancers also express u-PA in almost every patient. Thus, LRP is found in colorectal cancers that also express cathepsin B and u-PA.
When comparing the immunoreactivity of these three proteins, we were unable to find a correlation between cathepsin B and LRP, although it has been shown that cathepsin B is internalised via LRP (13) . There was no correlation between cathepsin B and u-PA either. Again, others have shown that both, cathepsin B and u-PA, are taken up by colorectal cancer cells in the same caveolae (55).
Interestingly, we found statistically significant correlations between the expression of LRP and u-PA in smooth muscle cells and in the cells of the tumor stroma. This finding can be explained by LRP serving as a receptor for u-PA and leading to its internalisation and degradation (26) . LRP might also influence proteolytic activity and tumor biology of colorectal cancer by binding u-PA. Thus, increased expression of LRP might lead to an increased cellular uptake of u-PA and could concentrate proteolytic activity on the cell surface by binding u-PA. The latter would be advantageous for tumor cells by facilitating invasive growth.
In summary, we show here that colorectal cancers express LRP mainly in cells of the desmoplastic stroma and at the invasion front. Its expression correlates with the expression of u-PA. We assume that LRP influences tumor biology by interfering with the balance of activation and inhibition of proteolytic processes. This topic merits further investigation.
